Home › Funds › Achmea Investment Management B.V. › RPRX

Achmea Investment Management B.V. position in RPRX

ROYALTY PHARMA PLC · Health Care

Achmea Investment Management B.V. reported holding 474,989 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$26.6M, representing 0.67% of its reported portfolio and ranking #42 among its reported holdings. Achmea Investment Management B.V. has disclosed RPRX holdings in 4 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)474.99K sh
Reported value held$26.63M
Portfolio Weight0.67%
First reportedQ2 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Achmea Investment Management B.V.'s RPRX position evolved

Achmea Investment Management B.V. first disclosed a stake in RPRX in Q2 2025 at 34,193 shares (US$1.2M). The position peaked in Q2 2026 at 474,989 shares, worth US$26.6M. Across 4 filings, Achmea Investment Management B.V. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 474,989 shares valued at US$26.6M — an increase of 442,307 shares quarter over quarter.. Notable position changes include a 1353% increase in Q2 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 34.19K $1.23M New
Q4 2025 34.19K $1.32M New
Q1 2026 32.68K $1.57M Reduce
Q2 2026 474.99K $26.63M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has Achmea Investment Management B.V. held RPRX?

Achmea Investment Management B.V. has disclosed RPRX holdings in 4 of the last 5 reported quarters, going back to Q2 2025.

What is Achmea Investment Management B.V.'s current position in RPRX?

As of Q2 2026, Achmea Investment Management B.V. holds 474.99K shares of RPRX (ROYALTY PHARMA PLC), valued at $26.63M, representing 0.67% of its reported portfolio and ranking #42.

Has Achmea Investment Management B.V. been buying or selling RPRX?

In the latest 13F filing (Q2 2026), Achmea Investment Management B.V. increased its position in RPRX. The position peaked in Q2 2026 at 474.99K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.